Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer

International Journal of Cancer

Volumn 74, Issue 4, 1997, Pages 407-415

  Dong, Ying ^a   Walsh, Michael D ^a   McGuckin, Michael A ^a   Cummings, Margaret C ^a   Gabrielli, Brian G ^b   Wrigiit, Gordon R ^a   Hurst, Terry ^a   Khoo, Soo Keat ^a   Parsons, Peter G ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LIFE TABLES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030865615     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z     Document Type: Article

References (29)

1. CAMPBELL, I.G., BEYNON, G., DAVIS, M. and ENGLEFIELD, P., LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer, 63, 222-225 (1995).
2. CHENEVIX-TRENCH, G., KERK, J., FRIEDLANDER, M.M., HURST, T., SANDERSON, B., COGLAN, M., WARD, B., LEARY, J. and KHOO, S.K., Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumours. Amer. J. hum. Genet., 55, 143-149 (1994).
3. DODSON, M.K.,CLIBY, W.A., Xu, H.-J., DELACEY, K.A., XU, S.-X., KEENEY, G.L., LI., J., PODRATZ, K.C., JENKINS, R.B. and BHNEDICT, W.F., Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res., 54, 610-613 (1994).
4. INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer (Pred. Oncol.), 74, 57-63 (1997).
5. ECCLES, D.M., BRETT, L., LESSELLS, A., GRUBER, L., LANE, D., STEEL, C.M. and LEONARD, R.C.F., Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Brit. J. Cancer, 65, 40-44 (1992).
6. ELIOPOULOS, A.G., KERR, D.J., HERPD, J., HODGKINS, L., KRAJEWSKI, S., REED, J.C. and YOUNG, L.S., The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11, 1217-1228 (1995).
7. HARTMANN, L.C., PODRATZ, K.C., KEENEY, G.L., KAMEL, N.A., EDMONSON, J.H., GRILL, J.P., Su, J.Q., KATZMANN, J.A. and ROCHE, P.C., Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. clin. Oncol., 12, 64-69 (1994).
8. KAPLAN, E.L. and MEIER, P., Nonparamotric estimation from incomplete observations. J. Amer. Statist. Assoc., 53, 457-481 (1958).
9. KASTAN, M.B., ONYEKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. and CRAIG, R.W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311 (1991).
10. KIM, T.M., BENEDICT, W.F., Xu, H.-J., Hu, S.X., GOSEWEHR, J., VELICESCU, M., YIN, E., ZHENG, J., D'ABLAING, G. and DUBEAU, L., Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumour and is associated with normal retinoblastoma gene expression. Cancer Res., 54, 605-609 (1994).
11. LEVESQUE, M.A., KATSAROS, D., Yu, H., ZOLA, P., SISMONDI, P., GIARDINA, G. and DIAMANDIS, E.P., Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer, 75, 1327-1338 (1995).
12. Li, S.B., SCHWARTZ, P.E., LEE, W.H. and YANG-FENG, T.L., Allele loss at the retinoblastoma locus in human ovarian cancer. J. nat. Cancer Inst., 83, 637-640 (1991).
13. Liu, Y., HEYMAN, M., WANG, Y., FALKMER, U., HISNG, C., SZEKELY, L. and EINHORN, S., Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int. J. Cancer, 58, 663-667 (1994).
14. LUKAS, J., PARRY, D., AAGAARD, L., MANN, J.D., BARTKOVA, J., STRAUSS, M., TETERS, G. and BAKTEK, J., Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375, 503-506 (1995).
15. MANTEL, N., Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-170 (1966).
16. MARKS, J.R., DAVIDOFF, A.M., KERNS, B.J., HUMPHREY, P.A., PENCE, J.C., DODGE, R.K., CLARKE-PEARSON, D.L., INGLEHART, J.D., BAST, R.C., JR. and BERCHUCK, A., Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51, 2979-2984 (1991).
17. MILNER, B.J., ALLAN, L.A., ECCLES, D.M., KITCHENER, H.C., LEONARD, R.C.F., KELLY, K.F., PARKIN, D.E. and HAITES, N.E., p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53, 2128-2132 (1993).
18. OSBORNE, R.J. and LEECH, V., Polymerase chain reaction allelotyping of human ovarian cancer. Brit. J. Cancer, 69, 429-438 (1994).
19. PEDLEY, J., ABLETT, E.M., PETTIT, A., DONN, I.S., STURM, R.A. and PARSONS, P.G., Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation. Oncogene, 13, 1335-1342 (1996).
20. RENNINSON, J., BAKER, B.W., MCGOWN, A.T., MURPHY, D., NORTON, J.D., Fox, B.W. and CROWTHER, D., Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Brit. J. Cancer, 69, 609-612 (1994).
21. RODABAUGH, K.J., BIGGS, R.B., QURESHI, J.A., BARRETT, A.J., WELCH, W.R., BELL, D.A., BERKOWJTZ, R.S. and MOK, S.C., Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumours. Oncogene, 11, 1259-1254 (1995).
22. SCHREIBER, E., MATTHIAS, P., MULLER, M.M. and SCHAFFNER, W., Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells. Nucleic Acids Res., 17, 6419 (1989).
23. SCHULTZ, D.C., VANDERVEER, L., BUETOW, K.H., BOENTE, M.P., OZOLS, R.F., HAMILTON, T.C. and GODWIN, A.K., Characterization of chromosome 9 in human ovarian neoplasia identities frequent genetic imbalance on 9q, and rare alterations involving 9p, including CDK2. Cancer Res., 55, 2150-2157 (1995).4
24. Ink4. Cancer Res., 54, 5816-5820 (1994).
25. WEINBERG, R.A., The retinoblastoma protein and cell cycle control. Cell, 81, 323-330 (1995).
26. XIONG, Y., ZHANG, H. and BEACH, D., Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Develop., 7, 1572-1583 (1993).
27. XU, H.J., HU, S.X., CAGLE, P.T., MOORE, G.E. and BENEDICT, W.F., Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res., 51, 2735-2739 (1991).
28. Xu, H.J., QUINLAN, D.C., DAVIDSON, A.C., Hu, S.X., SUMMERS, C.L., LI, J. and BENEDICT, W.F., Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J. nat. Cancer Inst., 86, 695-699 (1994).
29. YANG-FENG, T.L., HAN, H., CHEN, K.C., LI, S.B., CLAUS, B.E., CARCANCIU, M.L., CHAMBERS, S.K., CHAMBERS, J.T. and SCHWARTZ, P.E., Allelic loss in ovarian cancer. Int. J. Cancer, 54, 546-551 (1993).